The Chronic Kidney Disease (Chronic Renal Failure) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Kidney Disease (Chronic Renal Failure). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued products.
GlobalData tracks 170 drugs in development for Chronic Kidney Disease (Chronic Renal Failure) by 134 companies/universities/institutes. The top development phase for Chronic Kidney Disease (Chronic Renal Failure) is preclinical with 71 drugs in that stage. The Chronic Kidney Disease (Chronic Renal Failure) pipeline has 164 drugs in development by companies and six by universities/ institutes. Some of the companies in the Chronic Kidney Disease (Chronic Renal Failure) pipeline products market are: AstraZeneca, MD Healthcare and Bayer.
The key targets in the Chronic Kidney Disease (Chronic Renal Failure) pipeline products market include Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5), Apolipoprotein L1 (Apolipoprotein L or APOL1), and Endothelin 1 Receptor (Endothelin A Receptor or EDNRA).
The key mechanisms of action in the Chronic Kidney Disease (Chronic Renal Failure) pipeline product include Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Inhibitor with five drugs in Phase II. The Chronic Kidney Disease (Chronic Renal Failure) pipeline products include 15 routes of administration with the top ROA being Oral and 17 key molecule types in the Chronic Kidney Disease (Chronic Renal Failure) pipeline products market including Small Molecule, and Cell Therapy.
Chronic Kidney Disease (Chronic Renal Failure) overview
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol.
For a complete picture of Chronic Kidney Disease (Chronic Renal Failure)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
